EE385 Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME)

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.633
https://www.valueinhealthjournal.com/article/S1098-3015(22)00834-8/fulltext
Title : EE385 Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00834-8&doi=10.1016/j.jval.2022.04.633
First page :
Section Title :
Open access? : No
Section Order : 10565
Categories :
Tags :
Regions :
ViH Article Tags :